[Management of toxicity associated with chemotherapy for breast cancer].
Mukohara
Toru
T
Division of Hematology/Oncology, National Cancer Center Hospital East.
Mukai
Hirofumi
H
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D019072:Antibiotic Prophylaxis; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005334:Fever / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced* / Q000517:prevention & control*; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*; D000068878:Trastuzumab; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000932:Antiemetics; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D000068878:Trastuzumab